HC Wainwright Issues Pessimistic Forecast for CNTB Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Connect Biopharma to a loss of $0.30 per share from $0.26, while maintaining a Buy rating and $7.00 price target.
• Despite the reduced outlook, Connect Biopharma’s latest quarterly results beat expectations, reporting a $0.27-per-share loss versus the estimated $0.31 loss and revenue of $2.75 million against a $0.74 million forecast.
• Analyst sentiment remains broadly positive, with seven Buy ratings and one Sell rating; the stock has a Moderate Buy consensus and an average price target of $7.43, compared with its recent $2.55 price.

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2026 earnings estimates for Connect Biopharma in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.30) per share for the quarter, down from their prior estimate of ($0.26). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Connect Biopharma's current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Connect Biopharma's Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.19) EPS, FY2027 earnings at ($1.03) EPS, FY2028 earnings at ($0.81) EPS, FY2029 earnings at ($0.50) EPS and FY2030 earnings at ($0.10) EPS.

Other research analysts have also recently issued research reports about the stock. Piper Sandler assumed coverage on shares of Connect Biopharma in a report on Friday, June 26th. They issued an "overweight" rating and a $7.00 price target on the stock. Cantor Fitzgerald initiated coverage on Connect Biopharma in a research note on Thursday, May 21st. They set an "overweight" rating and a $4.00 price objective for the company. Wall Street Zen upgraded Connect Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday. Canaccord Genuity Group set a $7.00 target price on Connect Biopharma in a research note on Friday. Finally, Weiss Ratings downgraded Connect Biopharma from a "sell (d)" rating to a "sell (d-)" rating in a research report on Tuesday, June 30th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $7.43.

Connect Biopharma Stock Performance

NASDAQ CNTB opened at $2.55 on Monday. The company's 50 day simple moving average is $2.21 and its two-hundred day simple moving average is $2.48. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.37 and a quick ratio of 2.37. Connect Biopharma has a 1 year low of $1.23 and a 1 year high of $3.82. The stock has a market capitalization of $160.55 million, a PE ratio of -2.14 and a beta of -0.23.

Connect Biopharma (NASDAQ:CNTB - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.04. The firm had revenue of $2.75 million for the quarter, compared to analysts' expectations of $0.74 million.

Insider Buying and Selling at Connect Biopharma

In related news, Director James Huang acquired 150,000 shares of the stock in a transaction dated Friday, May 29th. The shares were purchased at an average price of $2.48 per share, for a total transaction of $372,000.00. Following the transaction, the director owned 13,310,000 shares in the company, valued at $33,008,800. This represents a 1.14% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 22.60% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CNTB. Bank of America Corp DE purchased a new stake in Connect Biopharma during the first quarter valued at about $41,000. ADAR1 Capital Management LLC purchased a new position in shares of Connect Biopharma in the 1st quarter worth about $1,945,000. Knott David M Jr boosted its holdings in shares of Connect Biopharma by 93.9% in the 1st quarter. Knott David M Jr now owns 387,835 shares of the company's stock worth $1,016,000 after purchasing an additional 187,835 shares in the last quarter. Simplify Asset Management Inc. bought a new position in shares of Connect Biopharma during the 1st quarter valued at about $135,000. Finally, Perceptive Advisors LLC bought a new position in shares of Connect Biopharma during the 4th quarter valued at about $2,235,000. 58.72% of the stock is currently owned by hedge funds and other institutional investors.

About Connect Biopharma

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company's lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source